U.S. markets open in 5 hours 23 minutes
  • S&P Futures

    4,357.00
    +13.75 (+0.32%)
     
  • Dow Futures

    33,917.00
    +119.00 (+0.35%)
     
  • Nasdaq Futures

    15,051.25
    +27.25 (+0.18%)
     
  • Russell 2000 Futures

    2,190.80
    +9.90 (+0.45%)
     
  • Crude Oil

    71.36
    +0.87 (+1.23%)
     
  • Gold

    1,778.00
    -0.20 (-0.01%)
     
  • Silver

    22.73
    +0.11 (+0.50%)
     
  • EUR/USD

    1.1732
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.3240
    0.0000 (0.00%)
     
  • Vix

    23.35
    -2.36 (-9.18%)
     
  • GBP/USD

    1.3640
    -0.0024 (-0.18%)
     
  • USD/JPY

    109.4600
    +0.2400 (+0.22%)
     
  • BTC-USD

    42,536.27
    -714.60 (-1.65%)
     
  • CMC Crypto 200

    1,060.31
    -3.54 (-0.33%)
     
  • FTSE 100

    7,033.41
    +52.43 (+0.75%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

IDT Biologika To Make J&J's COVID-19 Vaccine Using Takeda's Manufacturing Capacity

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Japan’s Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed an agreement with Germany-based contract manufacturer IDT Biologika GmbH to make Johnson & Johnson’s (NYSE: JNJ) single-dose COVID-19 vaccine.

  • Under the contract, the capacity at IDT’s Dessau site, previously reserved to make Takeda’s dengue vaccine candidate, will be used to make J&J’s COVID-19 vaccine for worldwide distribution.

  • After three months, the capacity will be returned to Takeda to resume manufacturing for its dengue vaccine’s planned launch.

  • This year, Merck & Co (NYSE: MRK) and Sanofi SA (NASDAQ: SNY) agreed to help make J&J’s vaccine.

  • Takeda is handling the Japanese approval process, import, and distribution of coronavirus vaccines from Moderna Inc (NASDAQ: MRNA) and Novavax Inc (NASDAQ: NVAX).

  • IDT is already producing AstraZeneca Plc’s (NASDAQ: AZN) COVID-19 vaccine.

  • Price Action: TAK shares are trading 2.25% higher at 18.85, and JNJ shares are up 0.41% at $160.25 in market trading hours on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.